Top Markets
#1 Velas Velas +480.92%
#2 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#3 Siren Siren +105.86%
#4 Venom Venom +60.87%
#5 Ontology Ontology +20.33%
#6 Gigachad Gigachad +17.65%
#7 Aria.AI Aria.AI +16.88%
#8 Scor Scor +16.32%
#9 Midnight Midnight +14.27%
#10 Echelon Prime Echelon Prime +13.26%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rank in Stocks #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Share Price
$0.0416118
Market Cap
$12.78M
Change (1 day)
1.72%
Change (1 year)
-22.01%
Country
AU
Trade Noxopharm Limited (NOX)

Category

Healthcare
P/E ratio for Noxopharm Limited (NOX)
P/E ratio as of March 2026 TTM: -3.25
According to Noxopharm Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.25. At the end of 2024 the company had a P/E ratio of -5.39.
P/E ratio history for Noxopharm Limited from 2016 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -3.25 0.53%
2025 -3.23 -40.02%
2024 -5.39 545.91%
2023 -0.83 -72.57%
2022 -3.04 -83.29%
2021 -18.21 -78.30%
2020 -83.90 1,577.80%
2019 -5.00 42.59%
2018 -3.51 -62.16%
2017 -9.27 19.11%
2016 -7.78 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -430.04%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -1,028.31%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -624.60%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -1,037.38%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -1,118.52%
AU
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.